Accès ouvert
2026
article
OpenAlex
Marija Balić, Gong, Priya Rastogi, Gregory Young et autres
PURPOSE: Detection of molecular residual disease (MRD) using circulating tumor DNA (ctDNA) is strongly associated with recurrence risk in early triple-negative breast cancer (TNBC). Prior studies suggest that ctDNA clearance during neoadjuvant therapy (NAT) may predict pathologic complete response (pCR) and enhance …
us, tw, de, ca, pt, fr
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Julia A. Grigorieva, David W. Hall, Omair Choudhry, Stephanie Birkey Reffey et autres
What is this summary about? This summary describes the α-CORRECT study and its key results. The study evaluated a new blood test that looks for tiny traces of cancer in patients with stage III colorectal cancer after treatment. What is the purpose …
us
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Marija Balic, Gong Tang, Priya Rastogi, Gregory Young et autres
Abstract PURPOSE: Presence of circulating tumor DNA (ctDNA) is strongly associated with recurrence risk in early triple-negative breast cancer (TNBC). NSABP B-59/GBG-96-GeparDouze evaluated atezolizumab or placebo added to neoadjuvant therapy (NAT) and as adjuvant therapy in 1,550 patients with stage II/III TNBC. …
us, de, ir, ca, pt, fr
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Gargi D. Basu, Paige Innis, Angela K. Deem, Arthur Starodynov et autres
BACKGROUND: ESR1 alterations present a common mechanism of resistance to endocrine therapy (ET) in hormonally driven tumors. The clinical significance of these alterations continues to evolve with newly approved targeted therapies and a range of ongoing investigational trials. METHODS: A retrospective study …
us
(code pays fourni par la source)
Accès ouvert
2026
other
OpenAlex
Gargi D. Basu, Paige Innis, Angela K. Deem, Arthur Starodynov et autres
Abstract Background ESR1 alterations present a common mechanism of resistance to endocrine therapy (ET) in hormonally driven tumors. The clinical significance of these alterations continues to evolve with newly approved targeted therapies and a range of ongoing investigational trials. Methods A retrospective …
us
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Gargi D. Basu, Paige Innis, Angela K. Deem, Arthur Starodynov et autres
Supplementary material 1
us
(code pays fourni par la source)
Accès ouvert
2026
other
OpenAlex
Gargi D. Basu, Paige Innis, Angela K. Deem, Arthur Starodynov et autres
Abstract Background ESR1 alterations present a common mechanism of resistance to endocrine therapy (ET) in hormonally driven tumors. The clinical significance of these alterations continues to evolve with newly approved targeted therapies and a range of ongoing investigational trials. Methods A retrospective …
us
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Gargi D. Basu, Paige Innis, Angela K. Deem, Arthur Starodynov et autres
Supplementary material 1
us
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Janine LoBello, Mark C. Evans, Gargi D. Basu, David W. Hall et autres
Introduction: Commercially available molecular residual disease (MRD) tests to detect circulating tumor DNA (ctDNA) in cell-free DNA (cfDNA) make various performance claims. We present real-world data on ctDNA positivity rates, associated tumor fractions in parts per million (PPM) in breast and colorectal …
us
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Jean-Paul De La O, Jess Hoag, Angela K. Deem, Min Wang et autres
// Jean-Paul De La O 1 , Jess R. Hoag 1 , Angela K. Deem 1 , Min Wang 1 , Arthur Starodynov 1 , Sameer S. Udhane 1 , Janine R. LoBello 1 , Nishitha Therala 1 , David W. Hall …
us
(code pays fourni par la source)
2025
conference-abstract
OpenAlex
Tadayoshi Hashimoto, Yoshiaki Nakamura, Greg Young, Melanie R. Palomares et autres
3590 Background: CRC is a leading cause of cancer-related mortality globally. Detection of molecular residual disease (MRD) is an early indicator of recurrence and may allow for timely intervention. Here, we evaluated an analytically validated tumor-informed ctDNA MRD assay (Oncodetect) in a …
jp, us
(code pays fourni par la source)
2025
article
OpenAlex
Sumeyye Samur, Ning Yan Gu, Gebra Cuyún Carter, Mert Sahinkoc et autres
e15600 Background: Colorectal cancer (CRC) is a prevalent solid tumor cancer. Patients remain at risk of recurrence despite curative-intent treatment. Early detection of recurrence allows timely intervention and may improve outcomes, particularly in high-risk patients. Standard-of-care (SoC) guidelines recommend routine surveillance following …
us
(code pays fourni par la source)